{"id":"treatment-of-encorafenib-binimetinib-ribociclib","rwe":[],"tags":[],"phase":"preclinical","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[],"contraindications":[],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"active","trials":["NCT05203172","NCT02159066","NCT01543698"],"aliases":[],"patents":[],"pricing":[],"allNames":"treatment of encorafenib & binimetinib & ribociclib","offLabel":[],"timeline":[{"date":"2023","type":"neutral","milestone":"Phase 2 Initiated","description":"Phase 2 trial (LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced B) — Melanoma"},{"date":"2029","type":"neutral","milestone":"Phase 4 Initiated","description":"Phase 4 trial (The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib fo) — Solid Tumors"}],"aiSummary":"Ribociclib is a small molecule inhibitor of Cyclin-dependent kinase 4. It is used in the treatment of cancer and solid tumors, as indicated by ClinicalTrials.gov.","brandName":"Treatment of Encorafenib & Binimetinib & Ribociclib","companyId":"pfizer","ecosystem":[],"mechanism":{"target":"","novelty":"","modality":"","drugClass":"Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime","explanation":"","oneSentence":"Encorafenib capsule and ribociclib capsules or tablets will be co-administered orally QD with binime","technicalDetail":""},"commercial":null,"references":[],"biosimilars":[],"companyName":"Pfizer Inc.","competitors":[],"genericName":"treatment-of-encorafenib-binimetinib-ribociclib","indications":{"approved":[],"offLabel":[],"pipeline":[{"name":"Solid Tumors","phase":"preclinical","trialId":"","patients":null,"diseaseId":"oncology","trialName":"","primaryEndpoint":"","expectedCompletion":""}]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05203172","phase":"Phase 4","title":"The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib fo","status":"Recruiting","sponsor":"Pfizer","isPivotal":false,"enrollment":46,"indication":"Solid Tumors","completionDate":"2029-07","primaryEndpoint":"The purpose of this clinical trial (called the FLOTILLA study) is to give continued access to the study medicines, as well as safety follow-up, for participants in prior clinical trials of encorafenib"},{"nctId":"NCT02159066","phase":"Phase 2","title":"LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced B","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":158,"indication":"Melanoma","completionDate":"2023-01","primaryEndpoint":"The primary purpose of this study is to assess the anti-tumor activity of LGX818/MEK162 in combination with targeted agents after progression on LGX818/MEK162 combination therapy, as well as the safet"},{"nctId":"NCT01543698","phase":"Phase 1/2","title":"A Phase Ib/II Study of LGX818 in Combination With MEK162 in Adult Patients With BRAF Dependent Advan","status":"Completed","sponsor":"Pfizer","isPivotal":false,"enrollment":189,"indication":"Solid Tumors Harboring a BRAF V600 Mutation","completionDate":"2023-03","primaryEndpoint":"This is a multi-center, open-label, dose finding, Phase Ib dose escalation study to estimate the MTD(s) and/or RP2D(s) for the dual combination of LGX818 and MEK162 and the triple combination of LGX81"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"","frequency":"","formulation":""},"crossReferences":{"chemblId":"CHEMBL3545110"},"formularyStatus":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"firstApprovalDate":"","companionDiagnostics":[],"firstApprovalCountry":null,"genericManufacturerList":[],"modality":"","enrichmentLevel":3,"visitCount":7,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}